News Releases

Date Title and Summary Additional Formats
Apr 05, 2021 Oyster Point Pharma Announces New Appointment to Board of Directors
George Eliades joins the Board of Directors PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular
Mar 02, 2021 Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Prescription Drug User Fee Act ( PDUFA) target action date is October 17, 2021 U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application Planned U.S. launch of OC-01 (varenicline) nasal spray in fourth quarter of
Feb 25, 2021 Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the
Feb 18, 2021 Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020 Phase 2 Clinical Trial Protocol of OC-01 (Varenicline) Nasal Spray in Patients with Neurotrophic
Feb 12, 2021 Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class